EP3199182 - COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL ARTERY DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1A [Right-click to bookmark this link] | |||
Former [2017/31] | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL VASCULAR DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1 | ||
[2017/37] | Status | No opposition filed within time limit Status updated on 11.06.2021 Database last updated on 22.08.2024 | |
Former | The patent has been granted Status updated on 03.07.2020 | ||
Former | Grant of patent is intended Status updated on 11.06.2020 | ||
Former | Examination is in progress Status updated on 26.05.2020 | ||
Former | Grant of patent is intended Status updated on 17.04.2020 | ||
Former | Examination is in progress Status updated on 02.10.2019 | ||
Former | Request for examination was made Status updated on 04.07.2017 | ||
Former | The international publication has been made Status updated on 11.04.2017 | Most recent event Tooltip | 08.07.2022 | Lapse of the patent in a contracting state New state(s): MK | published on 10.08.2022 [2022/32] | Applicant(s) | For all designated states Helixmith Co., Ltd 203dong, 1, Gwanak-ro Gwanak-gu, Seoul 08826 / KR | [2019/25] |
Former [2017/31] | For all designated states Viromed Co., Ltd. 203dong Institute of Basic Science Bldg. College of Natural Science Seoul National University Gwanak-ro 1, Gwanak-gu Seoul 08826 / KR | Inventor(s) | 01 /
JEONG, Jae-Gyun 102-402 Samsung Apt. 9 Yeongdeungpo-ro 3-gil Yeongdeungpo-gu Seoul 07276 / KR | 02 /
LEE, Jung Hun 108-1704 Heukseok Hangang Centreville Apt. 12 Heukseokhangang-ro Dongjak-gu Seoul 06981 / KR | 03 /
LEE, Nayeon Suite 208 46 Gwanak-ro 14-gil Gwanak-gu Seoul 08788 / KR | [2017/31] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
Former [2020/32] | J A Kemp LLP 14 South Square Gray's Inn London WC1R 5JJ / GB | ||
Former [2017/31] | advotec. Patent- und Rechtsanwälte Widenmayerstrasse 4 80538 München / DE | Application number, filing date | 15843739.2 | 25.09.2015 | [2017/31] | WO2015KR10240 | Priority number, date | KR20140129361 | 26.09.2014 Original published format: KR 20140129361 | [2017/31] | Filing language | KO | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2016048105 | Date: | 31.03.2016 | Language: | KO | [2016/13] | Type: | A1 Application with search report | No.: | EP3199182 | Date: | 02.08.2017 | Language: | EN | [2017/31] | Type: | B1 Patent specification | No.: | EP3199182 | Date: | 05.08.2020 | Language: | EN | [2020/32] | Search report(s) | International search report - published on: | KR | 31.03.2016 | (Supplementary) European search report - dispatched on: | EP | 29.03.2018 | Classification | IPC: | A61K48/00, A61K38/18, A61P9/10, A61P9/00 | [2017/31] | CPC: |
A61K38/195 (EP,US);
A61K38/18 (EP,CN,US);
A61K38/1833 (EP,US);
A61K48/00 (EP,CN,US);
A61K48/0016 (US);
A61P9/00 (EP);
A61P9/10 (EP)
(-)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2017/31] | Extension states | BA | Not yet paid | ME | Not yet paid | Validation states | MA | Not yet paid | Title | German: | ZUSAMMENSETZUNG ZUR PRÄVENTION ODER BEHANDLUNG VON PERIPHERER GEFÄSSERKRANKUNG UNTER VERWENDUNG DES HEPATOZYTENWACHSTUMSFAKTORS UND FAKTORS 1A AUS STROMAZELLEN | [2017/37] | English: | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL ARTERY DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1A | [2020/28] | French: | COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DES MALADIES VASCULAIRES PÉRIPHÉRIQUES UTILISANT LE FACTEUR DE CROISSANCE DES HÉPATOCYTES ET LE FACTEUR 1A DÉRIVÉ DES CELLULES STROMALES | [2017/37] |
Former [2017/31] | ZUSAMMENSETZUNG ZUR PRÄVENTION ODER BEHANDLUNG VON PERIPHERER GEFÄSSERKRANKUNG UNTER VERWENDUNG DES HEPATOZYTENWACHSTUMSFAKTORS UND FAKTORS 1 AUS STROMAZELLEN | ||
Former [2017/31] | COMPOSITION FOR PREVENTING OR TREATING PERIPHERAL VASCULAR DISEASE USING HEPATOCYTE GROWTH FACTOR AND STROMAL CELL DERIVED FACTOR 1 | ||
Former [2017/31] | COMPOSITION POUR LA PRÉVENTION OU LE TRAITEMENT DES MALADIES VASCULAIRES PÉRIPHÉRIQUES UTILISANT LE FACTEUR DE CROISSANCE DES HÉPATOCYTES ET LE FACTEUR 1 DÉRIVÉ DES CELLULES STROMALES | Entry into regional phase | 11.04.2017 | Translation filed | 11.04.2017 | National basic fee paid | 11.04.2017 | Search fee paid | 11.04.2017 | Designation fee(s) paid | 11.04.2017 | Examination fee paid | Examination procedure | 11.04.2017 | Examination requested [2017/31] | 11.04.2017 | Date on which the examining division has become responsible | 25.10.2018 | Amendment by applicant (claims and/or description) | 08.10.2019 | Despatch of a communication from the examining division (Time limit: M04) | 10.01.2020 | Reply to a communication from the examining division | 24.04.2020 | Communication of intention to grant the patent | 22.05.2020 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 12.06.2020 | Communication of intention to grant the patent | 23.06.2020 | Fee for grant paid | 23.06.2020 | Fee for publishing/printing paid | 23.06.2020 | Receipt of the translation of the claim(s) | Opposition(s) | 07.05.2021 | No opposition filed within time limit [2021/28] | Fees paid | Renewal fee | 26.09.2017 | Renewal fee patent year 03 | 25.09.2018 | Renewal fee patent year 04 | 13.09.2019 | Renewal fee patent year 05 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 25.09.2015 | AL | 05.08.2020 | AT | 05.08.2020 | CY | 05.08.2020 | CZ | 05.08.2020 | DK | 05.08.2020 | EE | 05.08.2020 | FI | 05.08.2020 | HR | 05.08.2020 | LT | 05.08.2020 | LV | 05.08.2020 | MC | 05.08.2020 | MK | 05.08.2020 | MT | 05.08.2020 | NL | 05.08.2020 | PL | 05.08.2020 | RO | 05.08.2020 | RS | 05.08.2020 | SE | 05.08.2020 | SI | 05.08.2020 | SK | 05.08.2020 | SM | 05.08.2020 | TR | 05.08.2020 | IE | 25.09.2020 | LU | 25.09.2020 | BE | 30.09.2020 | CH | 30.09.2020 | LI | 30.09.2020 | BG | 05.11.2020 | NO | 05.11.2020 | GR | 06.11.2020 | IS | 05.12.2020 | PT | 07.12.2020 | [2022/32] |
Former [2022/27] | HU | 25.09.2015 | |
AL | 05.08.2020 | ||
AT | 05.08.2020 | ||
CY | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
MC | 05.08.2020 | ||
MT | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SI | 05.08.2020 | ||
SK | 05.08.2020 | ||
SM | 05.08.2020 | ||
TR | 05.08.2020 | ||
IE | 25.09.2020 | ||
LU | 25.09.2020 | ||
BE | 30.09.2020 | ||
CH | 30.09.2020 | ||
LI | 30.09.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/37] | AL | 05.08.2020 | |
AT | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
MC | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SI | 05.08.2020 | ||
SK | 05.08.2020 | ||
SM | 05.08.2020 | ||
IE | 25.09.2020 | ||
LU | 25.09.2020 | ||
BE | 30.09.2020 | ||
CH | 30.09.2020 | ||
LI | 30.09.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/36] | AL | 05.08.2020 | |
AT | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
MC | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SI | 05.08.2020 | ||
SK | 05.08.2020 | ||
SM | 05.08.2020 | ||
LU | 25.09.2020 | ||
BE | 30.09.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/28] | AL | 05.08.2020 | |
AT | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
MC | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SK | 05.08.2020 | ||
SM | 05.08.2020 | ||
LU | 25.09.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/27] | AL | 05.08.2020 | |
AT | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
MC | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SM | 05.08.2020 | ||
LU | 25.09.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/25] | AL | 05.08.2020 | |
AT | 05.08.2020 | ||
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SM | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/22] | AT | 05.08.2020 | |
CZ | 05.08.2020 | ||
DK | 05.08.2020 | ||
EE | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RO | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
SM | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/21] | AT | 05.08.2020 | |
DK | 05.08.2020 | ||
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/12] | AT | 05.08.2020 | |
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
NL | 05.08.2020 | ||
PL | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/10] | AT | 05.08.2020 | |
FI | 05.08.2020 | ||
HR | 05.08.2020 | ||
LT | 05.08.2020 | ||
LV | 05.08.2020 | ||
PL | 05.08.2020 | ||
RS | 05.08.2020 | ||
SE | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
IS | 05.12.2020 | ||
PT | 07.12.2020 | ||
Former [2021/09] | AT | 05.08.2020 | |
FI | 05.08.2020 | ||
LT | 05.08.2020 | ||
SE | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
GR | 06.11.2020 | ||
PT | 07.12.2020 | ||
Former [2021/08] | FI | 05.08.2020 | |
LT | 05.08.2020 | ||
SE | 05.08.2020 | ||
BG | 05.11.2020 | ||
NO | 05.11.2020 | ||
PT | 07.12.2020 | ||
Former [2021/07] | FI | 05.08.2020 | |
LT | 05.08.2020 | ||
NO | 05.11.2020 | Documents cited: | Search | [Y]WO2012027170 (PROVASCULON INC [US], et al) [Y] 1-14*cf. abstract, page 18, last para. bridging with first para. at page 19, furthermore claims 1 and 11*; | [Y]WO2012170495 (PROVASCULON INC [US], et al) [Y] 1-14 *cf. abstract, page 1, lines 9-19, page 17, lines 11-16, claims 1 and 11*; | [Y]US2013095060 (HSIEH PATRICK C H [TW], et al) [Y] 1-14 *cf. claims 1 and 11*; | [X] - MAJKA M ET AL, "SDF-1 alone and in co-operation with HGF regulates biology of human cervical carcinoma cells", FOLIA HISTOCHEMICA ET CYTOBIOLOGICA 2006 POLISH HISTOCHEMICAL AND CYTOCHEMICAL SOCIETY POL, (2006), vol. 44, no. 3, ISSN 0239-8508, pages 155 - 164, XP009504281 [X] 1-13 *cf. abstract and introductive part at pages 155/156* DOI: http://dx.doi.org/10.5603/4562 | [Y] - MUROHARA ET AL, "Autologous adipose tissue as a new source of progenitor cells for therapeutic angiogenesis", JOURNAL OF CARDIOLOGY, NIHON SHINZOBYO GAKKAI, TOKYO, JP, vol. 53, no. 2, doi:10.1016/J.JJCC.2009.01.003, ISSN 0914-5087, (20090401), pages 155 - 163, (20090210), XP026014228 [Y] 1-13 *cf. summary, page 156, left col. 2nd para.* DOI: http://dx.doi.org/10.1016/j.jjcc.2009.01.003 | International search | [Y]WO03078568 (VIROMED CO LTD [KR], et al) [Y] 1-13 * See abstract; page 7, lines 4-6; claims 1-8; examples 1, 4; and sequence number 20. *; | [Y]WO2008121719 (CLEVELAND CLINIC FOUNDATION [US], et al) [Y] 1-13 * See abstract; paragraphs [0006], [0040], [0073], [0090]; and claims 1-8. *; | [Y]US7473425 (FUKUDA KEIICHI [JP], et al) [Y] 1-13 * See abstract; and table 1. *; | [A]WO2012025925 (RAPPAPORT FAMILY INST FOR RES [IL], et al) [A] 1-13* See abstract; and claims 1-24. *; | [Y]US8435953 (TABATA YASUHIKO [JP]) [Y] 1-13 * See abstract; column 14; claims 1-14, 18; and example 4. * |